DexCom (NASDAQ:DXCM) Upgraded at Wall Street Zen

DexCom (NASDAQ:DXCM) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

A number of other research analysts also recently weighed in on DXCM. Argus decreased their price target on DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Friday. Mizuho raised their target price on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Robert W. Baird set a $82.00 price target on shares of DexCom in a research report on Friday, October 31st. Truist Financial reissued a “buy” rating and issued a $82.00 price objective (down previously from $94.00) on shares of DexCom in a research report on Monday, November 3rd. Finally, Stifel Nicolaus began coverage on shares of DexCom in a research note on Tuesday, October 21st. They set a “buy” rating and a $85.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $88.86.

DexCom Stock Down 5.2%

Shares of DexCom stock traded down $3.02 during trading on Friday, reaching $55.00. The stock had a trading volume of 10,936,877 shares, compared to its average volume of 4,512,275. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $21.45 billion, a price-to-earnings ratio of 38.19, a P/E/G ratio of 1.43 and a beta of 1.40. DexCom has a 52 week low of $54.11 and a 52 week high of $93.25. The stock has a fifty day moving average price of $69.24 and a two-hundred day moving average price of $77.57.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm’s revenue was up 21.6% compared to the same quarter last year. During the same period last year, the company earned $0.45 earnings per share. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts predict that DexCom will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 500 shares of the business’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director directly owned 51,121 shares of the company’s stock, valued at $4,143,868.26. This represents a 5.10% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 5,383 shares of company stock valued at $434,274. 0.32% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SWS Partners acquired a new position in shares of DexCom during the 2nd quarter worth $1,661,000. Baader Bank Aktiengesellschaft acquired a new position in DexCom during the second quarter worth about $393,000. Jennison Associates LLC lifted its holdings in shares of DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after acquiring an additional 994,300 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in shares of DexCom by 4.9% in the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after purchasing an additional 6,800 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of DexCom by 85.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after purchasing an additional 557,576 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.